We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. (MRK) on Monday said a phase 3 study of its the cancer drug Keytruda in combination with chemotherapy in patients with triple-negative breast cancer met one of two primary endpoints.
The Kenilworth, N.J., drug maker said the combination showed a statistically significant improvement in pathological complete response rates compared with chemotherapy alone following the neoadjuvant, or presurgical, part of the neoadjuvant/adjuvant study regimen.
A pathological complete response is defined as a lack of all signs of cancer in tissue samples analyzed following completion of neoadjuvant therapy and definitive surgery.
Merck said the study will continue without changes to evaluate event-free survival, the other primary endpoint.
Triple-negative breast cancer makes up about 15% to 20% of all breast cancers and is usually more aggressive than the other types, according to the Dana-Farber Cancer Institute.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 29, 2019 07:41 ET (11:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
